|Bid||3.06 x 8000|
|Ask||3.07 x 3100|
|Day's Range||3.06 - 3.25|
|52 Week Range||0.67 - 6.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 13, 2017 - Mar 17, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
NEW YORK, Nov. 29, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Microsoft ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to MannKind Corp. Here are 5 ETFs with the largest exposure to MNKD-US. Comparing the performance and risk of MannKind Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
When quant billionaire David Shaw trades, the world listens. One of the most successful hedge funds of all time, Shaw has now made a number of intriguing moves in the last quarter including snapping up Valeant Pharmaceuticals International, Inc. (NYSE:VRX) and MannKind Corporation (NASDAQ:MNKD). Take a closer look at the fund’s top Q3 moves.
NEW YORK, NY / ACCESSWIRE / November 22, 2017 / U.S. markets closed at record highs on the strength of corporate earnings and a rally from the technology sector. The Dow Jones Industrial Average gained ...
Categories: Yahoo FinanceGet free summary analysis MannKind Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of MannKind Corp. – Halozyme Therapeutics, Inc., Albireo Pharma, Inc., Nektar Therapeutics, Aradigm Corporation, Novo Nordisk A/S Sponsored ADR Class B, Pfizer Inc., Eli Lilly and Company and Merck & ... Read more (Read more...)
A conversation with MannKind's CEO about the biotech's future with Afrezza, payers, partners, and pipeline candidates.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives MannKind Corp. a score of 8. Our analysis is based on comparing MannKind Corp. with the following peers – Halozyme Therapeutics, Inc., Albireo Pharma, Inc., Nektar Therapeutics, Aradigm Corporation, Novo Nordisk A/S Sponsored ADR Class B, Pfizer Inc., Eli Lilly and Company and Merck & Co., Inc. ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for MannKind Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
MannKind Corporation (NASDAQ:MNKD) could be ready to capture an enticing amount of diabetes market share despite what the Street mostly dismissed as a third quarter stumble for its inhalable insulin Afrezza. What has H.C. Wainwright's Oren Livnat so confident that more script growth lies ahead for the biotech firm?
It was a bad day to be a MannKind Corporation (NASDAQ:MNKD) investor yesterday after the biotech stock took an around 8% beating in the market on back of a dismal third quarter showing for diabetes drug Afrezza. Maxim analyst Jason Kolbert is shaking his head in frustration, relieved he recently ran to the sidelines.
WESTLAKE VILLAGE, Calif., Nov. 07, 2017-- MannKind Corporation today reported financial results for the third quarter and the nine months ended September 30, 2017. Afrezza net revenue grew 28% and 246% ...
NEW YORK, NY / ACCESSWIRE / November 7, 2017 / MannKind Corporation (NASDAQ: MNKD ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 7, 2017 at 5:00 PM Eastern ...
Drug and Medical Device stocks Appreciate in Value Before Big Clinical Trial Results and Clearances from the FDA or European Medicines Agency Investors who Recognize the Potential "Lightning Strike" ...
WESTLAKE VILLAGE, Calif., Oct. 27, 2017-- MannKind Corporation will release its 2017 third quarter financial results on Tuesday, November 7, 2017 and its management will host a conference call to discuss ...
NEW YORK, NY / ACCESSWIRE / October 25, 2017 / U.S. markets rebounded Tuesday on the strength of corporate earnings as better-than-expected earnings from Caterpillar and 3M lifted the Dow to new record ...
New 5.75% Convertible Senior Subordinated Exchange Notes due 2021 and Common Stock to be Issued in Exchange for Existing Convertible Senior Subordinated Exchange Notes due 2018. Fourth Amendment to Facility ...
WESTLAKE VILLAGE, Calif. and BELO HORIZONTE, Brazil, Oct. 23, 2017-- MannKind Corporation and BIOMM SA announced the submission of a registration dossier to ANVISA, seeking the approval of Afrezza ® inhalation ...
NEW YORK, NY / ACCESSWIRE / October 16, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...